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Abstract
Older adults are frequently prescribed atypical antipsychotic drugs and may be at a risk for
kidney-related adverse events. This population-based retrospective cohort study examined
the 90-day risk of acute kidney injury (AKI) and the potential reasons for AKI in 96,471
matched pairs of older adults who received and who did not receive a new atypical
antipsychotic drug prescription from 2003 to 2011 in Ontario. Atypical antipsychotic drug
use was associated with a higher risk of hospitalization with AKI (relative risk (RR) 2.06
[95% confidence interval (CI) 1.85–2.29]). The drug use was also associated with potential
reasons for AKI including hypotension (RR 2.16 [95% CI 1.81–2.57]), acute urinary
retention (RR 2.15 [95% CI 1.78–2.60]), and neuroleptic malignant
syndrome/rhabdomyolysis (RR 1.44 [95% CI 1.06–1.96]). Residual confounding is unlikely
to explain the observed associations entirely. This knowledge informs prescribing practice
and may help identify a drug-induced reason for AKI.

Keywords
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Chapter 1

1

Introduction

Atypical antipsychotic drugs (quetiapine, risperidone, and olanzapine) are frequently
prescribed to older adults and the incidence of its use in the population continues to
increase.1,2 In many jurisdictions these drugs are used to manage behavioural symptoms
of dementia, which is not an approved indication.2–5 Safety concerns have also been
raised about the use of these drugs in older adults.3,4,6,7 Acute kidney injury (AKI; a rapid
decline in kidney function) has been attributed to atypical antipsychotic drugs in several
case reports.8–12 Potential reasons for AKI include hypotension, acute urinary retention,
and neuroleptic malignant syndrome/rhabdomyolysis. The antagonistic properties of
atypical antipsychotic drugs against alpha-adrenergic, muscarinic acetylcholine,
serotonin, and dopamine receptors contributes to the adverse effects that may cause
AKI.8–30 Acute myocardial infarction and ventricular arrhythmias have also been
attributed to these drugs, and acute cardiac events can lead to hemodynamic
derangements and poor renal perfusion.31,32 However, no clinical or epidemiologic
studies have quantified the risk of AKI from atypical antipsychotic drugs. This
information would add to growing knowledge of potential adverse events from this drug
class – the U.S. Food and Drug Administration now warns of an increased risk of death in
older patients treated with these drugs versus placebo from analyses of placebocontrolled trials (averaging 10 weeks in duration).3 We conducted a population-based
retrospective matched cohort study of older adults in Ontario, Canada to characterize the
90-day risk of hospitalization with AKI associated with new atypical antipsychotic drug
use versus non-use. Moreover, we explored the potential reasons by which the kidney
injury may occur from the use of these drugs.
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Chapter 2

2

Literature Review

2.1 Acute kidney injury (AKI)
AKI is a sudden decline in kidney function, often following insults that cause structural
or functional alterations in the kidneys.33,34 The rapid loss in kidney function results in
accumulation of nitrogenous metabolic waste products including serum creatinine and
urea.
Measuring changes in serum creatinine concentration is a laboratory-based clinical tool
widely used to detect AKI.35–37 AKI is defined as an absolute rise in serum creatinine
concentration by 26.5 µmol/L or more within 48 hours or a relative rise by 50% or more
within seven days.37
The population-based incidence rate of AKI is 408.5 cases per 100,000 person-years and
is increasing by 10% each year.38,39 AKI is also a frequent clinical challenge with
incidence of 19.2 to 23.8 cases per 1000 hospitalizations.40,41 The mortality rate of
hospitalized patients with AKI approximates 20.3 to 28.1%.42 AKI is associated with
increased risks of developing permanent kidney failure (end-stage kidney disease) and inhospital mortality.40,43,44 AKI poses a financial burden to the healthcare system as patients
with the kidney injury have longer length of hospital stay and higher healthcare costs.40,43

2.2 Risk factors for AKI
A number of demographic factors, comorbid conditions, and certain medications have
been associated with AKI.
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2.2.1

Age

Older age is a risk factor for AKI due to the age-related reduction in kidney function
reserve and compromised ability of the kidneys to withstand acute insults.45,46 A
population-based study conducted in the U.S. observed progressively higher incidences
of AKI with increasing age (less than 50 years: 78.0 cases per 100,000 person-years; 50
to 59 years: 320.0 cases per 100,000 person-years; 60 to 69 years: 814.8 cases per
100,000 person-years; 70 to 79 years: 1809.1 cases per 100,000 person-years; 80 years or
older: 3545.4 cases per 100,000 person-years).38 Moreover, a prospective cohort study of
1,411 critically ill patients showed that those aged 65 years and older were more likely to
develop AKI compared to those younger than 65 years (OR 1.50 [95% CI 1.16–1.92]; P
= 0.002).47

2.2.2

Sex

Previous studies have implicated male sex with a higher risk of AKI.38,48 A populationbased study of 3,787,410 U.S. adults found a higher incidence of AKI in men than
women (443.1 cases per 100,000 person-years versus 330.4 cases per 100,000 personyears).38 Bagshaw et al.48 showed that men aged 65 years and older were at a
significantly greater risk of intensive care unit admission with AKI compared to women
of same age group (RR 2.2 [95% CI 1.5–3.2]; P < 0.0001).

2.2.3

Chronic kidney disease (CKD)

Measuring estimated glomerular filtration rate (GFR) is a widely used, serum creatininebased assessment of baseline kidney function.49 Briefly, GFR is the volume of fluid
filtered through the kidney glomeruli per unit time, based on serum creatinine
clearance.50,51 A normal GFR is greater than 80 mL/min/1.73 m2, while patients with a
GFR less than 10 mL/min/1.73 m2 frequently need ongoing dialysis treatments to
maintain their life.49,50 Chronic kidney disease (CKD) is defined as abnormalities of
kidney structure or function that is prolonged for greater than three months.49 CKD is
categorized into six stages according to its severity (i.e. the degree to which GFR is
reduced; stages 1, 2, 3a, 3b, 4, and 5; from less to more severe).51
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CKD is a potent risk factor for AKI as the chronic condition leaves patients more
vulnerable to acute insults to the kidneys.37,52 A population-based surveillance performed
in Alberta showed that patients with a history of CKD had a significantly higher risk of
intensive care unit admission with AKI compared to patients without such a history (RR
4.9 [95% CI 3.5–6.8]; P < 0.0001).48 Two retrospective cohort studies demonstrated a
graded relationship between the severity of CKD and the risk of hospitalization with
AKI.53,54 Pannu et al.53 demonstrated that, compared to patients with CKD Stage 3a,
those with more advanced stages of CKD were more likely to develop AKI. Patients with
CKD Stage 3b, 4, and 5 had ORs for hospitalization with AKI of 2.9 (95% CI 2.7–3.1),
6.2 (95% CI 5.7–6.8), and 18.3 (95% CI 16.5–20.3), respectively.53 James et al.54 had
similar findings from a cohort of 920,985 patients with CKD. In their study, patients with
CKD Stage 3b, 4, and 5 had respective rate ratios for hospitalization with AKI of 2.3
(95% CI 2.1–2.4), 5.6 (95% CI 5.1–6.2), and 13 (95% CI: 11–15) compared to patients
with CKD Stage 3a.54

2.2.4

Diabetes mellitus

Diabetes mellitus, characterized by the chronic elevation of blood glucose level, is one of
the leading causes of kidney disease.55–57 The scarring of kidney nephrons in diabetes
mellitus contributes to the reduction of kidney function.55–57 A population-based
surveillance study showed that adults diagnosed with diabetes mellitus had a significantly
greater risk of intensive care unit admission with AKI compared to those without such a
diagnosis (RR 10.3 [95% CI 7.7–13.6]; P < 0.0001).48 Moreover, a case-control study
that included 1,764 patients who acquired AKI and 600,820 patients who did not acquire
AKI during hospitalization suggested that diabetes mellitus is a risk factor for AKI.58 In
the study, patients who developed AKI were more likely to have pre-existing diabetes
mellitus compared to patients who did not develop the kidney injury (OR 2.07 [95% CI
1.86–2.30]).58

2.2.5

Cardiovascular disease

Normal kidney function is dependent on sufficient perfusion of the kidneys by the
cardiovascular system.33,59 Hemodynamic disturbances that arise from cardiovascular
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disorders may reduce renal perfusion and lead to decline in kidney function.33,59
Moreover, prolonged reduction in renal perfusion can lead to structural changes in the
kidneys.33,59 Bagshaw et al.48 showed that adults with a history of heart disease had a
significantly increased risk of intensive care unit admission with AKI compared to adults
without such a history (RR 24.0 [95% CI 18.5–31.2]; P < 0.0001). In the same study,
individuals with a history of stroke had with a significantly higher risk of AKI than those
without such a history (RR 22.0 [95% CI 15.6–31.0]; P < 0.0001).48 Poor left ventricular
function has also been identified as a risk factor for AKI following cardiac surgery.60 A
prospective cohort study of critically ill patients demonstrated that individuals with heart
failure were significantly more likely to acquire AKI compared to those without heart
failure (OR 2.18 [95% CI 1.12–4.44]; P = 0.02).47 A case-control study of hospitalized
patients found patients who suffered AKI were more likely to have pre-existing
congestive heart failure than patients who did not suffer the kidney injury (OR 9.0 [95%
CI 2.1–38.9]; P < 0.0001).61 Hsu et al.58 performed a case-control study of 602,584
hospitalized patients and found patients who acquired AKI had higher odds of having a
history of hypertension compared to patients who did not acquire the kidney injury (OR
1.41 [95% CI 1.25–1.58]).

2.2.6

Liver disease

Liver diseases such as cirrhosis predispose patients to AKI. Reasons include decreased
hyperdynamic circulation and decreased renal perfusion from blood volume depletion.62
A prospective cohort study conducted in an intensive care setting found patients with
with cirrhosis had a significantly higher odds of developing AKI compared to those
without cirrhosis (OR 2.18 [95% CI 1.16–4.10]; P = 0.01).47

2.2.7

Medications

A number of commonly prescribed medications can predispose patients to AKI.33,59,63,64
Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers
(ARBs), diuretics, and calcium channel blockers have anti-hypertensive properties and
AKI may occur with the use of these medications due to decreased renal perfusion.64,65
Moreover, the use of ACE inhibitors and ARBs can lead to reduced GFR due to their
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ability to decrease glomerular pressure by down-regulating the synthesis and activity of
angiotensin II.64,65 The use of non-steroidal anti-inflammatory drugs (NSAIDs) may also
precipitate AKI.66 NSAID-induced AKI has been reported in patients with pre-existing
kidney dysfunction, congestive heart failure, hypertension, or liver disease.67 A casecontrol study of 360 hospitalized patients found those who suffered AKI were
significantly more likely to have used ACE inhibitors, diuretics, or NSAIDs compared to
those who did not suffer the kidney injury (OR 2.0 [95% CI 1.2–3.6]; P = 0.014).68
Lipid lowering drug 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) may lead to rhabdomyolysis; a severe muscle injury characterized by the
breakdown of skeletal muscles.69 The destruction of skeletal muscles results in the release
of their contents, such as myoglobin, into the systemic circulation.69 Myoglobin is
nephrotoxic and may lead to AKI.69,70 The U.S. Food and Drug Administration warned of
the increased risk of myopathy associated with high dose statin based on the results of a
randomized controlled trial.71,72 In the randomized trial, 52 patients (0.9%) who received
high dose statin versus one patient (0.02%) patients who received low dose statin
developed myopathy.72 In the same trial, 22 patients (0.4%) who received high dose statin
versus no patient who received low dose statin developed rhabdomyolysis.72 In chart
reviews of patients hospitalized with rhabdomyolysis, statin use contributed to 4 to 13%
of the muscle injury.23,73

2.3 Atypical antipsychotic drugs and older adults
Atypical antipsychotic drugs (quetiapine, risperidone, and olanzapine) are psychoactive
medications originally approved for the treatment of schizophrenia and bipolar disorder.74
Although their mechanism of action is not entirely clear, the antipsychotic property of the
drugs has been attributed to brief blockade of dopamine receptors in the central nervous
system characterized by rapid dissociation from the receptors.75 Since their introduction
in the 1990s, atypical antipsychotic drugs have largely replaced conventional
antipsychotic drugs (the older class of antipsychotic drugs) due to their improved safety
and efficacy profiles.1,76 Unlike conventional antipsychotic drugs, atypical antipsychotic
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drugs produce minimal extrapyramidal side effects and improve both positive and
negative symptoms of psychosis.77–79 These favourable characteristics of atypical
antipsychotic drugs have been accredited to their ability to antagonize both dopamine and
serotonin receptors in the central nervous system.78,79
In many jurisdictions, atypical antipsychotic drugs are both frequently and increasingly
prescribed to older adults.2,5 In 2002, the prevalence of antipsychotic drug prescription
was 3% in Ontario residents 65 years and older and atypical antipsychotic drugs
accounted for 82.5% of all antipsychotic drugs dispensed.1 Risperidone was the most
commonly prescribed atypical antipsychotic drug (56.4%), followed by olanzapine
(29.6%) and quetiapine (13.9%).1 A common, off-label use of these drugs in older adults
has been the management of behavioural symptoms in dementia. In the U.S., none of the
atypical antipsychotic drugs have been approved for the management of behavioural
symptoms.3 In Canada, risperidone has been the only atypical antipsychotic drug
approved for the particular purpose.4 The annual incidence of antipsychotic drug
prescription among older patients with dementia has risen 20% in Ontario, from 1,512
prescriptions per 100,000 patients in 2002 to 1,813 prescriptions per 100,000 patients in
2007.2

2.4 Factors associated with atypical antipsychotic drug use
in older adults
A number of demographic factors and comorbid conditions have been associated with
atypical antipsychotic drug use.

2.4.1

Age

Previous studies of older adults have suggested patients with more advanced age are less
likely to use atypical antipsychotic drugs.80,81 A cross-sectional study of older British
adults found progressive reduction in the odds of using antipsychotic drugs with respect
to increasing age.80 Adults aged between 75 and 84 years were significantly less likely to
use antipsychotic drugs compared patients aged between 65 and 74 years (OR 0.61 [95%
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CI 0.47–0.79]; P < 0.05).80 In the same study, older adults aged 85 years and older also
had significantly lower odds of using the drugs compared to adults aged between 65 and
74 years (OR 0.36 [95% CI 0.27–0.46]; P < 0.05).80 Kamble et al.81 found similar
associations between age and antipsychotic drug use in their cross-sectional survey of
U.S. long-term care residents. When compared to residents aged between 65 and 74
years, those aged between 75 and 84 years did not have a significantly lower odds of
using the drugs (OR 0.93 [95% CI 0.77–1.13] P > 0.05).81 However, residents aged 85
years and older were significantly less likely to use antipsychotic drugs compared to
those aged between 65 and 74 years (OR 0.70 [95% CI 0.58–0.84]; P < 0.05).81

2.4.2

Sex

Previous studies of older adults showed that women were less likely to use atypical
antipsychotic drugs than men.81,82 For example, a cross-sectional study conducted in
long-term care facilities showed that female residents were significantly less likely to use
antipsychotic drugs compared to male residents (OR 0.80 [95% CI 0.70–0.93]; P <
0.05).81 Similarly, Bronskill et al.82 demonstrated that older women had a lower odds of
receiving antipsychotic drugs compared to older men (OR 0.69 [95% CI 0.64–0.75])
from the analysis of 19,870 long-term care residents in Ontario.

2.4.3

Residential status

Healthcare use by older adults who reside in long-term care facilities could differ
compared to those dwelling in communities.83,84 Lindesay et al.80 conducted a crosssectional survey of adults aged 65 years and older in the U.K. and found older adults
living in nursing homes were significantly more likely to use antipsychotic drugs
compared to those living in residential or voluntary homes (OR 1.97 [95% CI 1.52–2.55];
P < 0.05). Another cross-sectional study found similar results among older Swedish
adults.85 In the study, older adults living in long-term care facilities had an increased odds
of using antipsychotic drugs compared to those not living in such facilities (OR 2.72
[95% CI 1.29–5.74]).85
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2.4.4

Dementia and mental disorders

Quetiapine, risperidone, and olanzapine have been indicated for the treatment of
schizophrenia and bipolar disorder.74 Kamble et al.81 found long-term care residents with
schizophrenia had a significantly higher odds of using antipsychotic drugs than residents
without schizophrenia (OR 11.15 [95% CI 7.84–15.87]; P < 0.05). Moreover, they also
showed that residents with bipolar disorder were significantly more likely to use the
drugs compared to residents without the disorder (OR 3.97 [95% CI 2.52–6.24]; P <
0.05).81
Although risperidone has been the only atypical antipsychotic drug approved for the use
of managing behavioural symptoms of dementia in Canada, quetiapine and olanzapine
have also been widely used for this purpose.2,4 A retrospective cohort study conducted in
Ontario’s long-term care facilities found older patients with a history of dementia were
more likely to receive antipsychotic drugs compared to those without such a history (OR
3.52 [95% CI 3.24–3.82]).82 Similarly, in the U.S., long-term care residents diagnosed
with dementia were also significantly more likely to use antipsychotic drugs than
residents without such a diagnosis (OR 2.23 [95% CI 1.94–2.57]; P < 0.05).81 Also in
Finland, a cross-sectional analysis of 1,987 long-term care residents showed that atypical
antipsychotic drug use was more common among patients with dementia than those
without dementia (28.3% versus 24.2%; P = 0.062).86
In addition to the treatment of patients with schizophrenia, bipolar disorder, or dementia,
atypical antipsychotic drugs have also been used as an adjunctive treatment of major
depression and anxiety disorders.87–92 A cross-sectional survey of long-term care facilities
in the U.S showed that patients with anxiety disorder were significantly more likely to
use the antipsychotic drugs than those without such disorder (OR 1.70 [95% CI 1.43–
2.00]; P < 0.05).81 In the same study, patients who had depression also had a significantly
increased odds of using antipsychotic drugs compared to those who did not have
depression (OR 1.18 [95% CI 1.04–1.33]; P < 0.05).81 Moreover, a British crosssectional survey demonstrated that patients who used antidepressant drugs were
significantly more likely to also use antipsychotic drugs compared to those who did not
use antidepressant drugs. (OR 1.42 [95% CI 1.16–1.74]; P < 0.05).80
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2.5 Atypical antipsychotic drugs and potential reasons for
AKI
Potential reasons for AKI from atypical antipsychotic drug use include hypotension,
acute urinary retention, neuroleptic malignant syndrome/rhabdomyolysis, and acute
cardiac events (see Figure 1).

2.5.1

Hypotension

Hypotension (an abnormally low blood pressure) is a well-known cause of AKI, where
decreased renal perfusion leads to reduction in kidney function and when prolonged,
results in intrinsic damage to the kidneys.33,59 The ability of atypical antipsychotic drugs
to block alpha-adrenergic receptors has been postulated to result in vasodilation and a
subsequent reduction in blood pressure.78,93 Orthostatic hypotension is a type of
hypotension where systolic blood pressure decreases by at least 20 mmHg and/or
diastolic blood pressure declines by at least 10mmHg while transitioning from a lying to
standing position.94 Previous chart reviews of older patients have attributed orthostatic
hypotension to atypical antipsychotic drug use.95–97 For example, a chart review of 189
older patients with orthostatic hypotension attributed 5 (2.6%) cases to quetiapine use, 15
(7.9%) cases to risperidone use, and 4 (2.1%) cases to olanzapine use.95
Hypotension is a common adverse drug reaction observed in clinical trials of atypical
antipsychotic drugs in older adults.13–18 Sajatovic et al.13 performed an analysis of data
pooled from two randomized placebo-controlled trials (12 weeks in duration) that
included adults aged 55 years and older with bipolar disorder. Their analysis found
orthostatic hypotension in 5 out of 28 (17.9%) patients treated with quetiapine versus 1
out of 31 (3.2%) patients in the placebo group.13 Moreover, one patient treated with
quetiapine suffered unspecified kidney failure and died.13 In an open-label, single-arm
trial (13 months in duration) of quetiapine that included 184 older patients with
psychosis, 28 (15.2%) patients experienced orthostatic hypotension and 32 (17.4%)
patient experienced dizziness.14 The median time to onset for orthostatic hypotension and
dizziness was 18 and 15 days, respectively.14 In another open-label, single arm trial of
quetiapine involving 100 geriatric inpatients (4 weeks in duration), 9 (9.0%) patients
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suffered orthostatic hypotension and 27 (27.0%) patients experienced dizziness.15 A
randomized, open-label trial (6 months in duration) allocated 27 patients to risperidone
treatment and 34 patients to olanzapine treatment.17 In the risperidone group, 3 (11.1%)
patients developed orthostatic hypotension and 5 (18.5%) patients had unspecified renal
adverse events.17 In the olanzapine group, orthostatic hypotension occurred in 4 (11.8%)
patients.17 In a 12-week long open-label, single-arm study of risperidone that included
103 older patients with psychosis, orthostatic hypotension and dizziness were observed in
5 patients (4.9%) and 23 (22.3%) patients, respectively.16 In another open-label, singlearm trial of risperidone, which followed 110 older patients with psychosis for four weeks,
6 (5.5%) patients developed orthostatic hypotension and 32 (29.1%) patients experienced
dizziness.18

2.5.2

Acute urinary retention

Acute urinary retention is an abrupt inability to empty the bladder and this can cause
AKI.59,98 Muscarinic acetylcholine receptors are present in the urinary tract and are
involved in the biological pathways of micturition.8,98,99 Atypical antipsychotic drugs
have anticholinergic properties and thus, it has been postulated in some cases that the
drugs antagonize muscarinic acetylcholine receptors leading to acute urinary retention.8
Acute urinary retention has been attributed to the use of quetiapine, risperidone, or
olanzapine in case reports.8,20,21 In the report of two older patients who developed acute
urinary retention after olanzapine use, both suffered AKI.8

2.5.3

Neuroleptic malignant syndrome and rhabdomyolysis

Neuroleptic malignant syndrome is a serious adverse drug reaction that can occur from
antipsychotic drugs. Neuroleptic malignant syndrome is characterized by altered mental
status, autonomic dysfunction, extrapyramidal side effects, high fever, and elevated
serum creatine kinase level.100 Elevated creatine kinase level is a biomarker for muscle
damage and may also indicate rhabdomyolysis.69 Although the biological mechanism is
not entirely clear, the sudden blockade of dopamine receptors by atypical antipsychotic
drugs has been postulated to result in neuroleptic malignant syndrome.22,30 It has been
also hypothesized that, since dopaminergic neurons regulate the sympathetic nervous
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system, the down-regulation of their activity by atypical antipsychotic drugs can lead to
hyperactivity of the sympathetic nervous system and subsequent muscle damage.25,26,101
Previous chart reviews of approximately 100 patients hospitalized with rhabdomyolysis
attributed 5.5 to 7.5% of the cases to quetiapine use.23,24 A retrospective review of
patients hospitalized with olanzapine overdose showed a correlation between the quantity
of ingested olanzapine and the proportion of patients with creatine kinase level greater
than 500 IU/L (Pearson’s r = 0.91).102 Individual cases of rhabdomyolysis have also been
reported from the use of risperidone or olanzapine at therapeutic dosages and from the
use of quetiapine at therapeutic dosages and due to overdose.9–12,25–29,103,104 A common
complication of rhabdomyolysis is AKI, occurring in 15 to 46% of patients who suffer
the muscle breakdown (by mechanisms described in Section 2.2.7).73,105 Several case
reports have attributed AKI to the use of quetiapine, risperidone, or olanzapine where the
kidney injury was mediated by neuroleptic malignant syndrome and/or rhabdomyolysis.9–
12

Another case report described the development of AKI following rhabdomyolysis

induced by quetiapine overdose.103

2.5.4

Acute cardiac events

Acute cardiac events can result in hemodynamic instability and AKI may precipitate from
such events due to decreased renal perfusion.33,59 In a retrospective cohort study of
147,007 patients hospitalized with acute myocardial infarction, 28,545 (19.4%) of the
patients developed AKI.106 Pariente et al.31 conducted a retrospective cohort study in
Quebec to compare the risk of acute myocardial infarction between older patients with
dementia who were initiated on antipsychotic drug therapy and those were not initiated
on such a therapy. Among 10,969 antipsychotic drug users studied, 97.8% were initiated
on atypical antipsychotic drugs and the drug use versus non-use was associated with a 30day higher risk of acute myocardial infarction (HR 2.19 [95% CI 1.11–4.32]).31
In addition to acute myocardial infarction, ventricular arrhythmias have also been
attributed to atypical antipsychotic drug use.32 QT interval prolongation is a cardiac
condition that can lead to ventricular arrhythmia and sudden cardiac death.107 Atypical
antipsychotic drugs can induce QT interval prolongation by antagonizing cardiac
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potassium ion channels and thereby delaying repolarization of the heart.108 Individual
cases of QT interval prolongation have been attributed to quetiapine or risperidone use at
both therapeutic dosages and due to overdose.109–115 Ray et al.32 conducted a retrospective
cohort study of 279,900 U.S adults (mean age 46 years) to examine the relationship
between antipsychotic drug use and sudden cardiac death. In this study, antipsychotic
drug use versus non-use was associated with a significantly greater risk of sudden cardiac
death (rate ratio 2.26 [95% CI 1.88–2.72]; P < 0.001).32 There was a dose-dependent
relationship between the dose of antipsychotic drug used and the incidence of sudden
cardiac death, supporting a causal relationship between the drug use and sudden cardiac
death.32 The elevated risk of sudden cardiac death was consistently found in subgroups of
quetiapine users (rate ratio 1.88 [95% CI 1.30–2.71]), risperidone users (rate ratio 2.91
[95% CI 2.26–3.76]), and olanzapine users (rate ratio 2.04 [95% CI 1.52–2.74]).32

2.6 Atypical antipsychotic drugs and the risk of death in
older adults
In 2005, the U.S. Food and Drug Administration issued a boxed warning regarding the
increased mortality associated with atypical antipsychotic drug use in older patients with
dementia.3 A boxed warning is an alert that is present on the prescribing information of a
medication. The black box warning was based on the analyses of 17 placebo-controlled
trials (averaging about 10 weeks in duration), which demonstrated approximately 1.6 to
1.7-fold increase in mortality rate in older patients with dementia treated with atypical
antipsychotic drugs compared to patients in the placebo group.3 The incidence of death
was 4.5% in patients treated with atypical antipsychotic drugs versus 2.6% in the placebo
group.3 Later in the same year, Health Canada announced a similar warning, advising
healthcare professionals of the increased mortality associated with atypical antipsychotic
drug treatment.4 Health Canada’s advisory was based on 13 randomized placebocontrolled trials that showed approximately 1.6-fold increase in mortality rate in older
patients with dementia treated with atypical antipsychotic drugs compared to patients in
the placebo group.4 Subsequently, a meta-analysis of 15 randomized placebo-controlled
trials (10 to 12 weeks in duration) comparing atypical antipsychotic drug treatment with
placebo in older patients with dementia also showed supporting evidence for the
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warning.116 The meta-analysis showed that older patients treated with atypical
antipsychotic drugs were significantly more likely to die compared to those in the
placebo group (OR 1.54 [95% CI 1.06–2.23]; P < 0.01).116
Several population-based observational studies have also examined the risk of death
associated with atypical antipsychotic drug use in older adults.83,84,117 Gill et al.83
conducted a retrospective cohort study of older patients with dementia in Ontario to
characterize the association between newly initiated atypical antipsychotic drug use and
30-day mortality at the population-level. Their study found atypical antipsychotic drug
use versus non-use was associated with a higher risk of death in older patients with
dementia dwelling in communities (HR 1.31 [95% CI 1.02–1.70]).83 A similar
association between the drug use and mortality was found in older patients with dementia
residing in long-term care facilities (HR 1.55 [95% CI 1.15–2.07]).83 A subsequent
retrospective cohort study investigated the 30-day risk of serious events (defined as
events that required hospitalization or resulted in death) associated with newly
commenced atypical antipsychotic drug use in older patients with dementia.84 This study
found atypical antipsychotic drug use versus non-use was associated with an increased
odds of serious events in older patients with dementia dwelling in communities (OR 3.19
[95% CI 2.77–3.68]).84 A similar association between the drug use and serious events
was found in older patients with dementia residing in long-term care facilities (OR 1.92
[95% CI: 1.68–2.21]).84 In the U.S., Huybrechts et al.117 conducted a retrospective cohort
study to compare the risk of death among older long-term care residents newly initiated
on different atypical antipsychotic drugs.117 The mortality rate was 28.4 deaths per 100
person-years among quetiapine users, 36.2 deaths per 100 person-years among
risperidone users, and 36.7 deaths per 100 person-years among olanzapine users within
180 days after initiation of respective atypical antipsychotic drug treatment.117 This study
found a lower risk of death in quetiapine users compared to risperidone users (HR 0.80
[95% CI 0.74–0.86]).117 The risk of death in olanzapine users was not statistically
different from that of risperidone users (HR 1.01 [95% CI 0.95–1.07]).117
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Atypical Antipsychotic Drug Use

Hypotension
Acute Cardiac Events:
Acute Myocardial Infarction
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Rhabdomyolysis
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Urinary Tract
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Acute Kidney Injury
Figure 1: Putative biological mechanisms by which atypical antipsychotic drug use may
lead to AKI
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Chapter 3

3

Rationale and Research Questions

3.1 The need for research
Adverse drug reactions occur frequently among older adults with an incidence rate of
50.1 events per 1000 person-years.118 Approximately 28% of the adverse drug reactions
are preventable and kidney-related adverse events account for 27% of the preventable
adverse events.118,119 There currently exist genuine concerns about the safety of atypical
antipsychotic drug use in older adults. For example, this class of drugs is commonly and
increasingly being used for the unapproved indication of managing behavioural
symptoms of dementia despite the federal warnings that advise of the risk of death
associated with the drug treatment.2–4 Determining the risk of AKI associated with
atypical antipsychotic drug use will contribute to emerging knowledge regarding the
safety of their use in older adults. There exist several case reports attributing AKI to
atypical antipsychotic drug use, along with potential reasons why AKI may occur in this
setting.8–32 However, the association between atypical antipsychotic drug use and AKI
has not been characterized in previous clinical or epidemiologic investigations.
Therefore, we aimed to characterize the risk of hospitalization with AKI associated with
new atypical antipsychotic drug use versus non-use. Additionally, we intended to identify
potential reasons for AKI in this setting.

3.2 Research questions and hypotheses
3.2.1

Primary research question

Compared to non-use, is new atypical antipsychotic drug use associated with a higher risk
of hospitalization with AKI in older adults?
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Hypothesis: We hypothesize that, compared to non-use, new atypical antipsychotic drug
use is associated with a higher risk of hospitalization with AKI in older adults.

3.2.2

Secondary research questions

1) Compared to non-use, is new atypical antipsychotic drug use associated with a higher
risk of hospitalization with conditions that can be responsible for AKI in older adults?
These five conditions are: hypotension, acute urinary retention, neuroleptic malignant
syndrome/rhabdomyolysis, acute myocardial infarction, and ventricular arrhythmia.
Each of these conditions will be examined separately as a secondary outcome.
Hypothesis: We hypothesize that, compared to non-use, new atypical antipsychotic
drug use is associated with a higher risk of hospitalization with each of the conditions
that can be responsible for AKI in older adults.
2) Compared to non-use, is new atypical antipsychotic drug use associated with a higher
risk of all-cause mortality in older adults?
Hypothesis: We hypothesize that, compared to non-use, new atypical antipsychotic
drug use is associated with a higher risk of all-cause mortality in older adults.
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Chapter 4

4

Methods

4.1 Study design and setting
We conducted a population-based retrospective matched cohort study of older adults
using linked healthcare administrative databases in Ontario. Approximately 1.8 million
adults aged 65 years and older reside in Ontario.120 Older residents of Ontario have
comprehensive, universal healthcare that covers outpatient drug prescriptions, physician
services, and hospitalizations under a single-payer healthcare system.
We conducted this study according to a pre-specified protocol that was approved by the
research ethics board at Sunnybrook Health Sciences Centre in Toronto, Ontario. The
reporting of this study followed the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) guidelines (see Appendix A for checklist).121

4.2 Data sources
We used following six healthcare administrative databases housed at the Institute for
Clinical Evaluative Sciences to ascertain drug exposure, covariate information, and
outcome data:
1) Ontario Drug Benefit (ODB) Database
The ODB database stores records of all outpatient drug prescriptions dispensed to
patients aged 65 years and older in Ontario with a high level of accuracy (overall
error rate of less than 1%).122 We used this database to ascertain exposure to atypical
antipsychotic drugs and baseline medication use. We also acquired information on
patient residential status (community-dwelling or long-term care) and medical
specialty of the physicians who prescribed atypical antipsychotic drugs.
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2) Ontario’s Registered Persons Database (RPDB)
We used RPDB to attain information on patient demographics (age, sex, and vital
status), income (categorized into quintiles of average neighbourhood income), and
location of residence (urban or rural). Moreover, we used the vital status information
captured by this database to ascertain the outcome of all-cause mortality.
3) Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD)
CIHI-DAD contains diagnostic and procedural information on all hospitalizations
occurred in Ontario. A maximum of 25 unique diagnosis codes (for example, codes
for AKI, hypotension, or acute urinary retention) can be assigned to each
hospitalization. The hospital diagnosis codes were based on the International
Classification of Diseases, Ninth Revision (ICD-9) codes prior to 2002 and ICD-10
codes since 2002. We used both ICD-9 and ICD-10 codes to determine baseline
comorbid conditions (detailed in Appendix B). We used ICD-10 codes exclusively to
determine hospitalized outcomes as the cohort entry of the patients commenced in
2003 (detailed in Appendix C).
4) Ontario Health Insurance Plan (OHIP) Database
The OHIP database stores information on physician claims on inpatient and
outpatient services using fee codes. We used the information captured by the database
to identify baseline comorbid conditions in addition to the diagnostic information
attained from CIHI-DAD.
5) Ontario Mental Health Reporting System (OMHRS) Database
The OMHRS database contains demographic and health information on patients
admitted to adult mental health beds in Ontario. The diagnosis codes used record
health conditions in this database were based on the Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition (detailed in Appendix B). In addition to CIHI-DAD
and OHIP database, we used the diagnostic information stored in this database to
determine baseline psychiatric comorbid conditions.
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6) Cerner and Gamma-Dynacare Laboratory Databases
A subpopulation of patients in Southwestern Ontario had outpatient serum creatinine
and urine dipstick protein measurements available before cohort entry and was in the
catchment area of 12 hospitals in which linked serum creatinine laboratory
measurements were available through these laboratory datasets.123 We used the
information to assess baseline kidney function and to ascertain the outcome of AKI
defined using serum creatinine values.
All six databases have been repeatedly used to study health outcomes including adverse
drug reactions in previous studies.83,84,124–128

4.3 Patients
We accrued all adults aged 66 years and older in Ontario who were dispensed a new oral
outpatient prescription for an atypical antipsychotic drug (quetiapine, risperidone, or
olanzapine) between June 2003 and December 2011 to the drug user group. The date of
this prescription served as the ‘index date’ for the drug users. We then randomly assigned
an index date to all Ontario residents 66 years and older who were not dispensed a
prescription for any antipsychotic drug (according to the index date of the drug users) and
accrued them to the non-user group. For example, if more drug users were accrued
between 2005 and 2006, a larger proportion of nonusers would be randomly assigned an
index date between 2005 and 2006. We excluded the following patients from both
groups: (1) those with prescriptions for any antipsychotic drug in the 180 days prior to
their index date to ensure the drug users were newly prescribed, (2) those who were
discharged from a hospital in the two days before their index date to ensure the drug users
were newly initiated on an atypical antipsychotic drug in an outpatient setting and the
non-users had the potential to be newly initiated on such a drug in an outpatient setting,
and (3) those with an evidence of end-stage kidney disease (since the development of
AKI is no longer relevant). From the drug user group, we excluded individuals who
received a prescription for more than one type of antipsychotic drug on their index date to

21

compare mutually exclusive groups in subgroup analysis. From the non-user group, we
excluded individuals without any outpatient medication dispensed in the 90 days prior to
their index date to ensure that the non-users could have been prescribed a drug in Ontario.

4.4 Matching
The Consolidated Standards of Reporting Trials statement defined selection bias as a
“systematic error in creating intervention groups, causing them to differ with respect to
prognosis. That is, the groups differ in measured or unmeasured baseline characteristics
because of the way in which participants are selected for the study or assigned to their
study groups.”129 In randomized controlled trials, random allocation of treatment reduces
selection bias as the method, on average, distributes both measured and unmeasured
baseline factors similarly to the groups being compared.130,131 However, in cohort studies,
the exposure status is not randomly determined and thus, the exposed and unexposed
groups can differ in baseline characteristics that may affect the outcome.131
Consequently, cohort studies are susceptible to selection bias and this form of bias can
lead to confounding.131,132 Koepsell and Weiss133 stated “confounding occurs in
epidemiologic research when the measured association between an exposure and disease
occurrence is distorted by an imbalance between exposed and non-exposed persons in
regard to one or more other risk factors for the disease.” Matching is a method used to
reduce selection bias by forming exposed and unexposed groups that are similar with
respect to baseline characteristics that may affect the outcome.134 Therefore, we used the
method of matching to minimize selection bias and to control for potential confounding.
Propensity score matching allowed us to form a matched set of patients in the drug user
and non-user groups with similar probability of receiving an atypical antipsychotic drug
(the propensity score) conditional on observed baseline covariates.135,136 Following the
guidance provided by recent methodological studies, we incorporated the following three
types of variables into the propensity score136–138: (1) variables that are associated with
atypical antipsychotic drug use, (2) risk factors for AKI, and (3) variables that are
associated with both atypical antipsychotic drug use and AKI. We estimated the
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propensity score using a multivariable logistic regression model that included following
27 covariates: age (per year); sex (men or women); year of cohort entry (2003, 2004,
2005, 2006, 2007, 2008, 2009, 2010, or 2011); residential status (community-dwelling or
long-term care); evidence of dementia (yes or no), schizophrenia or other psychotic
disorder (yes or no), bipolar disorder (yes or no), major depression and/or anxiety
disorder (yes or no), chronic kidney disease (yes or no), cerebrovascular disease (yes or
no), chronic liver disease (yes or no), congestive heart failure (yes or no), coronary artery
disease (yes or no), diabetes mellitus (yes or no), hypertension (yes or no), and peripheral
vascular disease (yes or no); the use of anticonvulsant (yes or no), antidepressant (yes or
no), cholinesterase inhibitor (yes or no), lithium (yes or no), ACE inhibitor or ARB (yes
or no), beta-adrenergic antagonist (yes or no), calcium channel blocker (yes or no),
NSAID excluding aspirin (yes or no), potassium sparing diuretic (yes or no), nonpotassium sparing diuretic (yes or no), and statin (yes or no).
Subsequently, we matched a non-user to each drug user on the following 12
characteristics: the logit of the propensity score (within caliper of ± 0.2 standard
deviations139); age (within two years); sex; index date (within six months); residential
status (community-dwelling or long-term care); evidence of dementia (yes or no),
schizophrenia or other psychotic disorder (yes or no), bipolar disorder (yes or no), major
depression and/or anxiety disorder (yes or no), CKD (yes or no); a recently dispensed
medication from a pharmacy in the catchment area of linked hospital-based laboratory
measurements (yes or no)123; availability of serum creatinine measurement in the year
prior to the index date (yes or no). We matched the patients without replacement and
using greedy matching technique. Patients who were not matched successfully were
excluded from our analysis. Previously, it has been shown that optimal matching does not
perform better than greedy matching in forming balanced groups.140 Greedy matching
was preferred over optimal matching for the purpose of computing efficiency.
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4.5 Baseline characteristics
We assessed baseline comorbid conditions in the five years prior to the index date and
medication use in the 180 days prior to the index date of each atypical antipsychotic drug
user and non-user (see Appendix B for coding information). For the subpopulation of
patients whose laboratory measurements were available, we assessed their kidney
function in the year prior to their index date.

4.6 Outcomes
We followed patients for 90 days after the index date to assess the pre-specified
outcomes. We elected for the 90-day follow-up period to (1) focus on short-term adverse
outcomes, (2) avoid potential crossovers among different types of atypical antipsychotic
drugs that may occur with longer periods of follow-up, and (3) mimic the duration of
follow-up where safety outcomes were reported in clinical trials of atypical antipsychotic
drug treatment in older adults.3,4,116 The primary outcome was hospitalization with AKI.
The secondary outcomes were potential reasons for AKI (hospitalization with
hypotension, hospitalization with acute urinary retention, hospitalization with neuroleptic
malignant syndrome/rhabdomyolysis, hospitalization with acute myocardial infarction,
and hospitalization with ventricular arrhythmia), and all-cause mortality. Hospital
diagnosis codes used to ascertain the outcomes are presented in Appendix C. Because up
to 25 diagnosis codes can be assigned per hospitalization, patients with codes for several
study outcomes were accounted under each outcome present.
In our validation study, the hospital diagnosis code for AKI in Ontario identified a
median (interquartile range) absolute increase in serum creatinine of 98 µmol/L (43 to
200 µmol/L) from the most recent measured value prior to hospitalization, whereas its
absence identified a median (interquartile range) increase of 6 µmol/L (IQR −4 to 20
µmol/L).141 Patients hospitalized with AKI might or might not have the hospital diagnosis
code recorded. The code was more likely to be present for patients with more severe
forms of AKI, indicated by larger increases in serum creatinine.141 When compared
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against the reference standard of increases in serum creatinine, the specificity of the code
was greater than 95%.141 However, the sensitivity of the code ranged from 22 to 66%
with the metric being lower for milder forms of AKI and thus, the code underestimated
the true incidence of AKI.141 Therefore, in the subpopulation of patients whose serum
creatinine measurements were available, we examined AKI defined as an absolute
increase in serum creatinine concentration of 27 μmol/L or greater or a relative increase
by 50% or more from the most recently measured serum creatinine concentration in the
year prior to the patient’s index date (on the basis of the Acute Kidney Injury Network
staging system).35
The known validity of hospital diagnosis codes for secondary outcomes is presented in
Appendix C. Using reabstracted information written in a patient’s chart as the reference
standard, the hospital diagnosis code for hypotension and acute urinary retention had a
sensitivity of 72% and 86% and positive predictive value of 39% and 48%, each
respectively.142 Using the same reference standard, one of the two codes for acute
myocardial infarction had a sensitivity of 89% and positive predictive value of 87%.142
The codes for neuroleptic malignant syndrome/rhabdomyolysis and ventricular
arrhythmia have not been validated in our region and are not expected to be sensitive.
However, there was no reason to suspect differential misclassification of these diagnosis
codes between atypical antipsychotic drug users and non-users. Another secondary
outcome was all-cause mortality and the corresponding code has been found to be highly
accurate for identifying death with a sensitivity of 94% and specificity of 100%.143
We considered examining the robustness of our findings using tracer outcomes (also
referred to as falsification end-points).144,145 Tracer outcomes are those outcomes that are
hypothesized to be causally unrelated to the exposure; the presence of an association
between the exposure and tracer outcome would suggest that the observed associations in
the study may be confounded.144 However, after detailed review, we elected against this
given the wide range of adverse effects reported with atypical antipsychotic drugs.
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4.7 Statistical analyses
We compared baseline characteristics between atypical antipsychotic drug users and nonusers using standardized differences. This metric describes differences between group
means with respect to pooled standard deviation and indicates a meaningful difference if
greater than 0.10 (10%).136,146,147 The use of standardized differences has been
recommended over that of statistical hypothesis testing (using P values) for assessing
balance in baseline characteristics between propensity score matched groups.148–150 The
standardized difference is not influenced by sample size and thus, one can compare the
balance in the unmatched sample to that in the matched sample.149,150
We measured the risk for the primary and secondary outcomes in both absolute and
relative terms. We calculated absolute risk differences and 95% CIs using a method that
accounts for matching.151 Absolute risk difference was further expressed as the number
needed to harm (NNH; 1/absolute risk difference), a measure that indicates how many
patients need to receive an atypical antipsychotic drug to cause harm to one patient who
otherwise would not have been harmed. NNH was calculated for ease of interpretation
and not to imply causality. We used conditional logistic regression to estimate ORs and
95% CIs for the primary and secondary outcomes by using the non-user group as the
referent group.
We repeated the analysis of the primary outcome (hospitalization with AKI) in four prespecified subgroups: (1) evidence of CKD (present or absent), (2) antipsychotic drug type
(quetiapine, risperidone, or olanzapine), (3) antipsychotic drug dose (high dose or low
dose; high dose defined by a higher than median daily dose for the matched cohort
[quetiapine >25 mg/day, risperidone >0.5 mg/day, and olanzapine >2.5 mg/day]), and (4)
residential status (community-dwelling or long-term care). Each matched set of the drug
users and non-users were included in subgroups defined by the antipsychotic drug type
and dose based on the characteristics of the drug users.
CKD was identified using an algorithm of hospital diagnosis codes validated in our
region for older adults.152 The algorithm identified patients with a median (interquartile
range) estimated GFR of 38 mL/min/1.73 m2 (27 to 52 mL/min/1.73 m2), whereas its
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absence identified patients with a median (interquartile range) estimated GFR of 69
mL/min/1.73 m2 (56 to 82 mL/min/1.73 m2).152 The algorithm for CKD had a sensitivity
of 32% and specificity of 94% using an estimated GFR of 45 mL/min/1.73 m2 as the
referent standard.152 Due to its limited sensitivity, the algorithm underestimated the true
prevalence of CKD.152
All ORs were interpreted as RRs, which was appropriate given the observed incidence of
the study outcomes (less than 10%). We performed all analyses using SAS version 9.2
(SAS Institute, Cary, North Carolina, USA, 2008).
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5

Results

5.1 Cohort characteristics
5.1.1

Unmatched cohort

Cohort selection is presented in Figure 2 and baseline characteristics of the unmatched
and matched cohorts are presented in Table 1. Prior to matching, we identified 122,610
atypical antipsychotic drug users and 1,204,613 non-users. The drug users were older
than the non-users and were more likely to be female and reside in long-term care
facilities. The users were more likely to be diagnosed with dementia, schizophrenia or
other psychotic disorder, bipolar disorder, major depression and/or anxiety disorder,
chronic kidney disease, cerebrovascular disease, congestive heart failure, and coronary
artery disease compared to the non-users. Moreover, the drug users were more likely to
use anticonvulsants, antidepressants, cholinesterase inhibitors, and lithium. The drug
users were less likely to use ACE inhibitors or ARBs and statins compared to the nonusers (Table 1). Information on income was not available for 676 (0.6%) drug users and
4,380 (0.4%) non-users. Location of residence could not be ascertained for 234 (0.2%)
drug users and 1,142 (0.1%) non-users.

5.1.2

Matched cohort

After matching, 96,471 pairs of atypical antipsychotic drug users and non-users remained
in the cohort. The two groups were well balanced showing no meaningful difference in
the 29 baseline characteristics measured: age, sex, income, year of cohort entry, location
of residence, residential status, 12 comorbid conditions, and use of 11 medications (Table
1). The mean age was 81 years, 64.6% of patients were women and 23.9% resided in
long-term care facilities. More than half of patients (53.9%) had a diagnosis of dementia.
7.6% of patients were diagnosed with schizophrenia or other psychotic disorder and 4.9%
was diagnosed with bipolar disorder. A diagnosis of major depression and/or anxiety
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disorder was made on 18.9% of patients. The most frequently prescribed atypical
antipsychotic drug was risperidone (45.3%), followed by quetiapine (35.9%) and
olanzapine (18.8%). The median (interquartile range) daily dose for quetiapine was 25
(25–50) mg/day, for risperidone was 0.5 (0.3–0.6) mg/day, and for olanzapine was 2.5
(2.5–5.0) mg/day. The prescriber information was not available for 10.7% of the atypical
antipsychotic drug users. When the prescriber information was available (89.3% of the
drug users), general practitioners (82.0%) were the most frequent prescribers of atypical
antipsychotic drugs, followed by psychiatrists (7.1%) and geriatricians (4.7%). Income
could not be ascertained for 448 (0.5%) drug users and 386 (0.4%) non-users. Location of
residence could not be identified for 177 (0.2%) drug users and 109 (0.1%) non-users.
Baseline characteristics of patients from the subpopulation in Southwestern Ontario with
available serum creatinine measurements are presented in Table 2. Within the matched
cohort, there were 1,442 pairs of atypical antipsychotic drug users and non-users were
from the subpopulation. The two groups were well balanced showing no meaningful
differences in the 29 baseline characteristics including age, sex, income, year of cohort
entry, location of residence (urban or rural), residential status (community-dwelling or
long-term care), 10 comorbid conditions, use of 10 medications, baseline serum
creatinine concentration, estimated GFR, and urine dipstick protein (Table 2). However,
the drug users were more likely to have a diagnosis of cerebrovascular disease than the
non-users (7.0% versus 4.4%; standardized difference = 0.11). The number of patients
with bipolar disorder, use of lithium, and estimated GFR less than 15 mL/min/1.73m2
was too few (less than five) and were not reported for reasons of patient privacy.

5.2 Main analysis
The primary outcome was 90-day hospitalization with AKI, assessed with a hospital
diagnosis code and with serum creatinine values. The 90-day incidence of hospitalization
with AKI assessed with a hospital diagnosis code in the atypical antipsychotic drug user
group was 1.06% (1,022 events) and in the non-user group was 0.52% (500 events).
Atypical antipsychotic drug use versus non-use was associated with a greater risk of
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hospitalization with AKI (RR 2.06 [95% CI 1.85–2.29]; absolute risk difference 0.54%
[95% CI 0.46%–0.62%]; NNH 185 [95% CI 161–216]). In the subpopulation where AKI
was assessed using serum creatinine values, the 90-day incidence of hospitalization with
AKI in atypical antipsychotic drug user group was 1.46% (21 events) and in the non-user
group was 0.55% (8 events). Atypical antipsychotic drug use versus non-use was
associated with an increased risk of hospitalization with AKI (RR 2.63 [95% CI 1.16–
5.93]; absolute risk difference 0.90% [95% CI 0.17%–1.63%]; NNH 111 [95% CI 61–
585]) (see Section 4.6 for the serum creatinine-based definition of AKI).
The potential reasons for AKI assessed with hospital diagnosis codes are considered as
secondary outcomes and are presented in Table 3. Atypical antipsychotic drug use versus
non-use was associated with a 90-day higher risk of hospitalization with hypotension (RR
2.16 [95% CI 1.81–2.57]), acute urinary retention (RR 2.15 [95% CI 1.78–2.60]),
neuroleptic malignant syndrome/rhabdomyolysis (RR 1.44 [95% CI 1.06–1.96]), acute
myocardial infarction (RR 1.34 [95% CI 1.19–1.51]), and ventricular arrhythmia (RR
1.72 [95% CI 1.37–2.14]). Another secondary outcome investigated was all-cause
mortality and is also presented in Table 3. Atypical antipsychotic drug use versus non-use
was associated with a 90-day higher risk of all-cause mortality (RR 2.68 [95% CI 2.56–
2.81]).

5.3 Subgroup analysis
The four subgroup analyses performed are presented in Table 4. The presence of CKD
did not influence the relative association between atypical antipsychotic drug use and
hospitalization with AKI (Interaction P = 0.15). The absolute risk difference in the
incidence of hospitalization with AKI between the drug users and non-users was greater
in patients with CKD (1.82% [95% CI 1.23%–2.41%]) compared to patients without
CKD (0.44% [95% CI 0.37%–0.52%]). The association between atypical antipsychotic
drug use and hospitalization with AKI was not modified by antipsychotic drug type
(Interaction P = 0.13) nor by antipsychotic drug dose (Interaction P = 0.49). The risk of
hospitalization with AKI associated with atypical antipsychotic drug use versus non-use
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was higher in community-dwellers (RR 2.37 [95% CI 2.08–2.71]) than in long-term care
residents (RR 1.53 [95% CI 1.27–1.85]) (Interaction P < 0.001).
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215,543 Ontario residents 66 years or
older who were dispensed a new oral
outpatient prescription for an atypical
antipsychotic drug (quetiapine,
risperidone, or olanzapine) between
June 2003 and December 2011

92,933 Patients excluded
from the atypical
antipsychotic drug user
group
58,212 Prescriptions for
any antipsychotic drug in
the 180 days prior to the
index date
28,802 Discharged from a
hospital in the two days
prior to the index date
1,065 Evidence of endstage kidney disease
4,854 A prescription for
more than one type of
antipsychotic drug on the
index date

122,610 Atypical
antipsychotic drug users

26,139 Unmatched

96,471 Atypical
antipsychotic drug users
Figure 2: Cohort selection

1,726,930 Ontario residents 66 years or
older were not dispensed a new oral
outpatient prescription for any
antipsychotic drug between June 2003
and December 2011

522,317 Patients excluded
from the atypical
antipsychotic drug non-user
group
34,232 Prescriptions for
any antipsychotic drug in
the 180 days prior to the
index date
13,298 Discharged from a
hospital in the two days
before the index date
6,047 Evidence of endstage kidney disease
468,740 Without at least
one outpatient medication
dispensed in the 90 days
prior to the index date

1,204,613 Atypical
antipsychotic drug non-users

1,108,142 Unmatched

96,471 Atypical antipsychotic
drug non-users

Table 1: Baseline characteristics of atypical antipsychotic drug users and non-usersa

Demographics
Age, mean (SD), years
Women
Income quintilec
1 (low)
2
3 (middle)
4
5 (high)
Year of cohort entry
2003–2004
2005–2006
2007–2008
2009–2010
2011
Rural residenced
Long-term care
Comorbid conditionse
Dementia
Schizophrenia or other
psychotic disorder
Bipolar disorder
Major depression and/or
anxiety disorder

Users
(n=122,610)

Unmatched
Non-Users
(n=1,204,613)

Standardized
Differenceb

Users
(n=96,471)

Matched
Non-Users
(n=96,471)

Standardized
Differenceb

81 (8)
77,508 (63.2)

76 (7)
687,831 (57.1)

0.74
0.12

81 (8)
62,326 (64.6)

81 (8)
62,326 (64.6)

0.00
0.00

27,282 (22.3)
25,465 (20.8)
23,838 (19.4)
23,106 (18.8)
22,243 (18.1)

234,967 (19.5)
253,463 (21.0)
234,892 (19.5)
235,555 (19.6)
241,356 (20.0)

0.07
0.00
0.00
0.02
0.05

21,347 (22.1)
20,189 (20.9)
18,866 (19.6)
18,159 (18.8)
17,462 (18.1)

20,704 (21.5)
19,813 (20.5)
18,649 (19.3)
18,497 (19.2)
18,422 (19.1)

0.01
0.01
0.01
0.01
0.03

26,712 (21.8)
29,640 (24.2)
25,286 (20.6)
26,795 (21.9)
14,177 (11.6)
15,811 (12.9)
37,598 (30.7)

229,290 (19.0)
272,475 (22.6)
251,863 (20.9)
289,588 (24.0)
161,397 (13.4)
172,157 (14.3)
32,457 (2.7)

0.07
0.04
0.01
0.05
0.05
0.04
0.81

19,561 (20.3)
22,501 (23.3)
19,979 (20.7)
22,281 (23.1)
12,149 (12.6)
12,288 (12.7)
23,063 (23.9)

19,582 (20.3)
22,523 (23.3)
19,882 (20.6)
22,323 (23.1)
12,161 (12.6)
13,400 (13.9)
23,063 (23.9)

0.00
0.00
0.00
0.00
0.00
0.04
0.00

73,839 (60.2)
15,263 (12.4)

90,115 (7.5)
14,095 (1.2)

1.81
0.79

51,983 (53.9)
7,322 (7.6)

51,983 (53.9)
7,322 (7.6)

0.00
0.00

9,673 (7.9)

11,413 (0.9)

0.56

4,769 (4.9)

4,769 (4.9)

0.00

27,250 (22.2)

74,960 (6.2)

0.61

18,239 (18.9)

18,239 (18.9)

0.00
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Table 1 (continued)
Chronic kidney disease
Cerebrovascular disease
Chronic liver disease
Congestive heart failure
Coronary artery diseasef
Diabetes mellitusg
Hypertensionh
Peripheral vascular
disease
Medication usei
Anticonvulsant
Antidepressant
Cholinesterase inhibitor
Lithium
ACE inhibitor or ARB
Beta-adrenergic
antagonist
Calcium channel
blocker
NSAID (excluding
aspirin)
Potassium sparing
diuretic
Non-potassium sparing
diuretic
Statin

10,341 (8.4)
9,079 (7.4)
4,020 (3.3)
24,999 (20.4)
50,601 (41.3)
20,435 (16.7)
84,209 (68.7)

70,440 (5.8)
28,550 (2.4)
36,398 (3.0)
134,486 (11.2)
420,958 (34.9)
208,112 (17.3)
883,364 (73.3)

0.11
0.30
0.01
0.28
0.13
0.02
0.10

6,819 (7.1)
6,178 (6.4)
3,080 (3.2)
18,662 (19.3)
38,976 (40.4)
15,919 (16.5)
66,913 (69.4)

6,819 (7.1)
6,145 (6.4)
3,054 (3.2)
19,641 (20.4)
40,071 (41.5)
16,720 (17.3)
68,829 (71.3)

0.00
0.00
0.00
0.03
0.02
0.02
0.04

2,587 (2.1)

17,790 (1.5)

0.05

1,888 (2.0)

2,089 (2.2)

0.01

14,457 (11.8)
31,278 (25.5)
36,347 (29.6)
1,324 (1.1)
54,674 (44.6)

45,907 (3.8)
85,243 (7.1)
25,683 (2.1)
1,317 (0.1)
617,052 (51.2)

0.39
0.66
1.41
0.22
0.13

9,606 (10.0)
20,481 (21.2)
22,457 (23.3)
599 (0.6)
43,908 (45.5)

10,764 (11.2)
21,638 (22.4)
20,081 (20.8)
531 (0.6)
45,249 (46.9)

0.04
0.03
0.06
0.01
0.03

37,391 (30.5)

365,976 (30.4)

0.00

29,574 (30.7)

30,216 (31.3)

0.01

33,166 (27.0)

344,285 (28.6)

0.03

26,607 (27.6)

27,499 (28.5)

0.02

20,720 (16.9)

220,395 (18.3)

0.04

16,626 (17.2)

16,587 (17.2)

0.00

7,998 (6.5)

69,486 (5.8)

0.03

6,243 (6.5)

6,590 (6.8)

0.01

41,896 (34.2)

355,874 (29.5)

0.10

32,567 (33.8)

33,832 (35.1)

0.03

41,975 (34.2)

539,520 (44.8)

0.21

34,019 (35.3)

34,523 (35.8)

0.01
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Table 1 (continued)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; NSAID, Non-steroidal antiinflammatory drug; SD, standard deviation
a
Data are presented as the number (percentage) of patients, unless otherwise reported.
b
Standardized difference describes differences between group means with respect to pooled standard deviation and indicates a
meaningful difference if greater than 0.10 (10%).146,147,150
c
Income was not available for 676 (0.6%) drug users and 4,380 (0.4%) non-users in the unmatched cohort and 448 (0.5%) drug
users and 386 (0.4%) non-users in the matched cohort.
d
Location of residence was not available for 234 (0.2%) drug users and 1,142 (0.1%) non-users in the unmatched cohort and 177
(0.2%) drug users and 109 (0.1%) non-users in the matched cohort.
e
Comorbid conditions in the 5 years preceding the index date were considered.
f
Coronary artery disease includes diagnoses of angina and receipt of coronary artery bypass graft surgery and percutaneous
coronary intervention.
g
Diabetes mellitus and were defined by use of any diabetic medication in the 6 months preceding the index date.
h
Hypertension was defined by use of any antihypertensive medication in the 6 months preceding the index date.
i
Medication use in the 180 days preceding the index date were considered.
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Table 2: Baseline characteristics of atypical antipsychotic drug users and non-users in the subpopulation with available serum
creatinine measurements (Matched)a

Demographics
Age, mean (SD), years
Women
Income quintilec
1 (low)
2
3 (middle)
4
5 (high)
Year of cohort entry
2003–2004
2005–2006
2007–2008
2009–2010
2011
Rural residenced
Long-term care
Comorbid conditionse
Dementia
Schizophrenia or other psychotic disorder
Bipolar disorderf
Major depression and/or anxiety disorder
Chronic kidney disease
Cerebrovascular disease
Chronic liver disease

Users
(n=1,442)

Non-Users
(n=1,442)

Standardized
Differenceb

79 (7)
938 (65.0)

80 (7)
938 (65.0)

0.01
0.00

333 (23.1)
270 (18.7)
287 (19.9)
224 (15.5)
287 (19.9)

312 (21.6)
278 (19.3)
279 (19.3)
235 (16.3)
302 (20.9)

0.04
0.02
0.02
0.02
0.02

173 (12.0)
319 (22.1)
315 (21.8)
404 (28.0)
231 (16.0)
163 (11.3)
177 (12.3)

176 (12.2)
317 (22.0)
323 (22.4)
400 (27.7)
226 (15.7)
167 (11.6)
177 (12.3)

0.01
0.00
0.01
0.01
0.01
0.01
0.00

614 (42.6)
42 (2.9)
…
286 (19.8)
48 (3.3)
101 (7.0)
62 (4.3)

614 (42.6)
42 (2.9)
…
286 (19.8)
48 (3.3)
63 (4.4)
49 (3.4)

0.00
0.00
…
0.00
0.00
0.11
0.05
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Table 2 (continued)
Congestive heart failure
Coronary artery diseaseg
Diabetes mellitush
Hypertensioni
Peripheral vascular disease
Medication usej
Anticonvulsant
Antidepressant
Cholinesterase inhibitor
Lithiumf
ACE inhibitor or ARB
Beta-adrenergic antagonist
Calcium channel blocker
NSAID (excluding aspirin)
Potassium sparing diuretic
Non-potassium sparing diuretic
Statin
Kidney functionk
Baseline serum creatinine concentration,
median (IQR), µmol/L
Estimated GFR, median (IQR), mL/min/1.73m2 l
Estimated GFR
≥60 mL/min/1.73m2
45-59 mL/min/1.73m2
30-44 mL/min/1.73m2
15-29 mL/min/1.73m2
<15 mL/min/1.73m2 f
Urine dipstick proteinm

281 (19.5)
559 (38.8)
269 (18.7)
1,081 (75.0)
23 (1.6)

281 (19.5)
593 (41.1)
272 (18.9)
1,096 (76.0)
22 (1.5)

0.00
0.05
0.01
0.02
0.01

97 (6.7)
399 (27.7)
254 (17.6)
…
714 (49.5)
506 (35.1)
435 (30.2)
265 (18.4)
119 (8.3)
515 (35.7)
571 (39.6)

127 (8.8)
413 (28.6)
225 (15.6)
…
732 (50.8)
505 (35.0)
422 (29.3)
246 (17.1)
120 (8.3)
533 (37.0)
585 (40.6)

0.08
0.02
0.05
…
0.02
0.00
0.02
0.03
0.00
0.03
0.02

83 (69–103)

82 (68–100)

0.01

64 (50–80)

66 (50–79)

0.02

824 (57.1)
346 (24.0)
209 (14.5)
58 (4.0)
…

870 (60.3)
336 (23.3)
179 (12.4)
53 (3.7)
…

0.07
0.02
0.06
0.02
…
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Table 2 (continued)
negative
0.3g/L or more

146 (73.4)
53 (26.6)

153 (69.9)
66 (30.1)

0.08
0.08

Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; GFR, glomerular
filtration rate; IQR, interquartile range; NSAID, Non-steroidal anti-inflammatory drug; SD, standard deviation
a
Data are presented as the number (percentage) of patients, unless otherwise reported.
b
Standardized difference describes differences between group means with respect to pooled standard deviation and indicates a
meaningful difference if greater than 0.10 (10%).146,147,150
c
Income was not available for 41 (2.8%) drug users and 36 (2.5%) non-users.
d
Location of residence was not available for less than five drug users and was available for all non-users.
e
Comorbid conditions in the 5 years preceding the index date were considered, respectively.
f
Number of patients with bipolar disorder, use of lithium, and estimated GFR <15mL/min/1.73m2 were too few (less than five)
and were not available for the reasons of patient privacy.
g
Coronary artery disease includes diagnoses of angina and receipt of coronary artery bypass graft surgery and percutaneous
coronary intervention.
h
Diabetes mellitus and were defined by use of any diabetic medication in the 6 months preceding the index date.
i
Hypertension was defined by use of any antihypertensive medication in the 6 months preceding the index date.
j
Medication use in the 180 days preceding the index date were considered.
k
Baseline serum creatinine measurements were taken as a routine care at a median (IQR) of 83 (32-183) and 119 (50-208) days
prior to the index date for the drug user and non-user groups, respectively.
l
Estimated GFR was calculated using the CKD-EPI equation153: 141 × min([Serum creatinine concentration in µmol/L/88.4]/k,1)a
× max([serum creatinine concentration in µmol/L/88.4]/k,1)-1.209 × 0.993Age ×1.018 [if female] × 1.159 [if black]; k=0.7 if female
and 0.9 if male; a=-0.329 if female and -0.411 if male; min=the minimum of serum creatinine concentration/k or 1; max=the
maximum of serum creatinine concentration/k or 1. Information on race was not available in our data sources and all patients were
assumed not to be of African Canadian race; African Canadians represented less than 5% of the population of Ontario in 2006.154
m
Urine dipstick protein measurements were available for 199 drug users and 219 non-users.
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Table 3: Potential reasons for AKI and all-cause mortality in atypical antipsychotic drug users and non-users
Events, No (%)
Users
Non-Users
(n=96,471)
(n=96,471)
Potential reasons for AKIa
Hypotension
Acute urinary retention
Neuroleptic malignant
syndrome/rhabdomyolysis
Acute myocardial infarction
Ventricular arrhythmia
All-cause mortality
All-cause mortality

Relative Risk
(95% CI)

Absolute Risk
Difference
(95% CI), %

NNH
(95% CI)

393 (0.41)
340 (0.35)

182 (0.19)
158 (0.16)

2.16 (1.81–2.57)
2.15 (1.78–2.60)

0.22 (0.17–0.27)
0.19 (0.14–0.23)

457 (374–588)
530 (427–698)

101 (0.10)

70 (0.07)

1.44 (1.06–1.96)

0.03 (0.01–0.06)

3112 (1704–17963)

629 (0.65)
211 (0.22)

471 (0.49)
123 (0.13)

1.34 (1.19–1.51)
1.72 (1.37–2.14)

0.16 (0.10–0.23)
0.09 (0.05–0.13)

611 (433–1036)
1096 (779–1849)

6,688 (6.93)

2,658 (2.76)

2.68 (2.56–2.81)

4.18 (3.99–4.37)

24 (23–25)

Abbreviations: AKI, acute kidney injury; CI, confidence interval; NNH, number need to harm
a
Events (and the proportion of patients with an event) were assessed using hospital diagnosis codes. The true event rate is
underestimated for some outcomes as the codes for the outcomes have high specificity, but low sensitivity. Similarly, NNH is
underestimated for this reason.
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Table 4: The association between atypical antipsychotic drug use and hospitalization with AKI, examined in subgroups
defined by evidence of CKD, antipsychotic drug type, antipsychotic drug dose, and residential status
No. with Events/No. at Risk (%)a
Users
Evidence of CKD
CKD
280/6,819 (4.11%)
No CKD
742/89,652 (0.83%)
Antipsychotic Drug Type
Quetiapine
379/34,672 (1.09%)
Risperidone 468/43,693 (1.07%)
Olanzapine 175/18,106 (0.97%)
Antipsychotic Drug Doseb
High dose
386/34,089 (1.13%)
Low dose
636/62,382 (1.02%)
Residential Status
Community
740/73,408 (1.01%)
dwelling
Long-term
282/23,063 (1.22%)
Care

Non-Users

Relative Risk
(95% CI)

Interaction
Test
(P value)

Absolute Risk
Difference
(95% CI), %

NNH
(95% CI)

156/6,819 (2.29%)
344/89,652 (0.38%)

1.82 (1.49–2.22)
2.16 (1.90–2.46)

0.15

1.82 (1.23–2.41)
0.44 (0.37–0.52)

55 (41–82)
225 (194–269)

202/34,672 (0.58%)
232/43,693 (0.53%)
66/18,106 (0.36%)

1.89 (1.59–2.24)
2.04 (1.74–2.39)
2.65 (2.00–3.52)

0.13

0.51 (0.38–0.65)
0.54 (0.42–0.66)
0.60 (0.43–0.77)

196 (155–267)
185 (152–237)
166 (130–230)

180/34,089 (0.53%)
320/62,382 (0.51%)

2.16 (1.81–2.59)
2.00 (1.75–2.29)

0.49

0.60 (0.47–0.74)
0.51 (0.41–0.60)

165 (135–213)
197 (166–244)

316/73,408 (0.43%)

2.37 (2.08–2.71)

0.58 (0.49–0.66)

173 (151–203)

184/23,063 (0.80%)

1.53 (1.27–1.85)

0.42 (0.24–0.61)

235 (164–414)

< 0.001

Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; NNH, number need to harm
a
Acute kidney injury (AKI) (and the proportion of patients with AKI) were assessed using a hospital diagnosis code. The true
event rate of AKI is underestimated for some outcomes as the code for AKI has high specificity, but low sensitivity. Similarly,
NNH is underestimated for this reason.
b
High dose was defined as: >25 mg/day quetiapine, >0.5mg/day risperidone, and >2.5mg/day olanzapine and low dose was
defined as: ≤25 mg/day quetiapine, ≤0.5mg/day risperidone, and ≤2.5 mg/day olanzapine.
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Chapter 6

6

Discussion

6.1 Summary and interpretation of study results
Although previous case reports have attributed AKI to atypical antipsychotic drug use,
their relationship had not been investigated.8–12 In this retrospective matched cohort study
of older adults, we followed new atypical antipsychotic drug users and non-users for 90
days to characterize the risk of AKI associated with the initiation of atypical
antipsychotic drug use. We demonstrated that newly initiated atypical antipsychotic drug
use versus non-use was associated with a higher risk of hospitalization with AKI in older
adults.
Although the precise mechanism of AKI from these drugs requires further elucidation,
our results suggest that hypotension, acute urinary retention, neuroleptic malignant
syndrome/rhabdomyolysis, and acute cardiac events might have biologically mediated the
observed association between the drug use and AKI. First, AKI might have developed
from decreased renal perfusion.13–18,33,59,78,93,95–97 The drugs have the ability to induce
hypotension by antagonizing alpha-adrenergic receptors which are involved in the
regulation of vascular contractility.78,93 Furthermore, it is plausible that the hemodynamic
derangements and decreased renal perfusion that resulted from acute cardiac events might
have precipitated AKI.31–33,59,106–115 Second, acute urinary retention induced by the drugs
might have led to AKI.8,20,21,59,98,99,155 The drugs are able to block muscarinic
acetylcholine receptors, which are present in the urinary tract and involved in
micturition.8,98,99 Lastly, AKI might have occurred from the structural damage incurred
by the myoglobin released from damaged muscles in patients suffering neuroleptic
malignant syndrome/rhabdomyolysis following the drug use.9–12,22–30,101–104 The ability
for the drugs to suddenly block dopamine receptors have been postulated to explain this
adverse effect.22,30 The down-regulation of the dopaminergic neurons could have also
resulted in the hyperactivity of the sympathetic nervous system and resultant muscle
damage.
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Patients with CKD are especially predisposed to AKI.37,52–54 In our study, the absolute
risk difference in the incidence of hospitalization with AKI between atypical
antipsychotic drug users and non-users were greater in patients with CKD compared to
those without CKD. Patients with CKD should be warned about the potential risk of AKI
and be closely monitored when commenced on atypical antipsychotic drug
therapy.37,48,52–54
The association found between atypical antipsychotic drug use and AKI was consistent in
patients who received quetiapine, risperidone, or olanzapine.
The antipsychotic drug dose did not influence the association between the drug use and
AKI. A possible explanation for this observation would be that the starting dose was used
to define high dose versus low dose in our study. Since dose titration is a common
therapeutic strategy in older patients, the starting dose is unlikely to represent the enddose.78 An alternative speculation would be that the rate of dose titration rather than the
absolute amount of dose influences the development of AKI.
While an association between atypical antipsychotic drug use and hospitalization with
AKI was observed in both community-dwellers and long-term care residents, the
association was more pronounced in community-dwellers. This finding is consistent with
a previous study that found the risk of short-term serious events associated with atypical
antipsychotic drug use to be higher in community-dwellers than in long-term care
residents.84 A possible explanation for this finding is less surveillance following
treatments in older adults residing in the community compared to those living in longterm care facilities.
Our findings expand on accumulating evidences that have advised caution in the use of
atypical antipsychotic drugs in older adults.3,4,31,32,83,84,116 In our study, atypical
antipsychotic drug use versus non-use was also associated with a higher risk of all-cause
mortality. This finding supports the federal advisory of the U.S. and Canada that warns of
the risk of death associated with the drug use in older patients with dementia.3,4 In our
observational study, the 90-day incidence of death was 6.9% in the drug users versus
2.8% in the non-users. These rates similar to those presented by the U.S. Food and Drug
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Administration from the analyses of placebo-controlled trials that included older patients
(averaging 10 weeks in duration).3 In their analysis, the incidence of death was 4.5% in
the drug-treated group versus 2.6% in the placebo group.3 The association between
atypical antipsychotic drug use and short-term mortality has also been evidenced in a
meta-analysis of randomized placebo-controlled trials (10 to 12 weeks in duration) and a
previous population-based cohort study.83,116
In our observational study, the incidence of hospitalization with hypotension was 0.41%
in the atypical antipsychotic drug user group and 0.19% in the non-user group (i.e. RR of
2.16 [95% CI 1.81–2.57]). In the analysis of two randomized placebo-controlled trials
that included patients aged 55 years and older, the incidence of orthostatic hypotension
was 5.5-fold higher in patients treated with an atypical antipsychotic drug compared to
patients in the placebo group.13 Unlike our observational study, which used a hospital
diagnosis code to identify hypotension (a code which is expected to be insensitive and to
detect only severe forms of hypotension), the incidence of orthostatic hypotension in the
analysis of two randomized trials was 17.9% (5 out of 28 patients) in the drug-treated
group versus 3.2% (1 out of 31 patients) in the placebo group.13

6.2 Study strengths and limitations
Our study has several strengths. To our knowledge, this is the first population-based
study that characterized the risk of AKI associated with atypical antipsychotic drug use.
Furthermore, our study explored potential reasons why AKI may develop from the drug
use. The population-based associations observed in our study were supported by the
known biological effects of the drugs.8–30 The use of provincial healthcare administrative
data on universal prescription drug coverage allowed us to accrue a large, representative
sample of older adults who received atypical antipsychotic drugs. This enabled us to
estimate the risk of less common but serious adverse drug events with high levels of
precision and generalizability. Many previous population-based studies that examined the
safety of atypical antipsychotic drugs in older adults only included those with
dementia.31,83,84,128 In comparison, the inclusion of older patients with a variety of mental
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disorders (schizophrenia or other psychotic disorder, bipolar disorder, and major
depression and/or anxiety disorder) enabled the study results to be applicable to a wider
range of patients. Finally, we employed a ‘new user’ design, which allows observational
studies to mimic clinical trials in that patients are immediately followed from the time of
treatment initiation.156 This method enabled us to reduce potential bias that may arise
from accruing prevalent drug users who have survived initial periods of the
pharmacotherapy.156
Experimental studies provide the strongest evidence for whether or not an exposure has
an effect on the risk of a disease.157 However, clinical trials are costly and the relatively
small number of patients enrolled in the trials makes the estimation of risk for relatively
rare adverse drug events difficult.131,158 Large observational studies can complement the
findings of clinical trials by enabling the investigation of uncommon but important
adverse drug events with adequate statistical power. Moreover, these observational
studies can include vulnerable groups of patients who may be excluded from clinical
trials and better reflect what occurs in routine clinical settings where treatments and
monitoring are less regulated than in clinical trials.31,32,83,159,160
A major concern of observational studies is the non-random distribution of exposure; in
the case of our study, atypical antipsychotic drug use. The two groups being compared
may be different on several characteristics including those that are risk factors for the
outcomes of interest such as AKI.133 Despite achieving similarity in 29 baseline
characteristics measured in the drug users and non-users, the concern for residual
confounding cannot be eliminated, as there may be other unmeasured patient
characteristics that differ between the drug user and non-user groups that may influence
the risk of AKI. However, we propose residual confounding is unlikely to explain the
entire observed association between the drug use and AKI in this study for several
reasons. First, the association is supported by numerous case reports and the known
biological effects of these drugs.8–30 It is difficult to conceive that a particular cause of
AKI, such as neuroleptic malignant syndrome/rhabdomyolysis, in the 90-day follow-up
(a risk observed in the present study) was not related to new atypical antipsychotic drug
use.9–12,22–30 Second, the magnitude of the effect size was robust, with most point
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estimates of RRs being greater than two. Even if the risk estimates are partly attenuated
after accounting for unmeasured confounders, the results would still suggest that atypical
antipsychotic drug-induced AKI is an important adverse drug event at the populationlevel given the high prevalence and increasing incidence of prescriptions for the drugs in
older adults.1,2
In addition to the potential for residual confounding, our study has several other
shortcomings. The absolute risk difference for some outcomes was underestimated
because the hospital diagnosis codes for some conditions were insensitive.141,142 To
address this concern for the primary outcome of AKI, we supplemented our findings and
observed consistent results in a subpopulation with available serum creatinine
measurements. We generalize our findings only to older adults, as reliable drug data was
not available on patients under age 65 in our data sources. Although younger patients
may be expected to have improved resistance to AKI, it is worth noting that the doses of
atypical antipsychotic drugs used in younger patients are also generally higher than of
those used in older patients.74 Moreover, our findings may be only applicable to the use
of quetiapine, risperidone, and olanzapine; the most commonly used atypical
antipsychotic drugs in Ontario.1,2 However, it remains prudent to use other atypical
antipsychotic drugs cautiously as well (such as aripiprazole, ziprasidone, and
paliperidone) as federal warnings for increased mortality extend to the entire drug
class.3,4,155,161–169

6.3 Study implications
Our results suggest that AKI may result from atypical antipsychotic drug use and that the
kidney injury may be mediated by hypotension, acute urinary retention, neuroleptic
malignant syndrome/rhabdomyolysis, acute cardiac events. We propose the study results
are sufficiently compelling that they should be acted on to help prevent adverse drug
events. There should be judicious use of atypical antipsychotic drugs for managing
behavioural symptoms of dementia, as the adverse effects of the drugs can offset
potential benefits.170,171 Using these drugs for the management behavioural symptoms of
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dementia are not an approved indication by regulatory authorities (with the exception of
risperidone in Canada).3,4 Patients with CKD may be at the highest absolute risk of AKI
from use of these drugs. When an atypical antipsychotic drug is initiated, patients,
especially those with CKD, can be informed about the potential adverse effects of the
drug. Preventative measures may include monitoring for a decrease in urine output,
performing a bladder scan to check for retention of urine, and measuring serum creatinine
and blood pressure in follow-up. If a patient does present to medical attention with AKI,
this drug class can be considered as a potential cause of the kidney injury so that it can be
discontinued to promote resolution.

6.4 Recommendations for future studies
Future studies are warranted to better characterize the risk of AKI associated with
atypical antipsychotic drug use including potential reasons for the kidney injury. Future
studies may benefit by employing improved tools to measure the outcomes, such as blood
pressure measurement for the assessment of hypotension or post-void residual urine
measurement for the assessment of acute urinary retention. Moreover, future studies
should further investigate the association between the drug use and the outcomes by
including younger drug users and newly emerging atypical antipsychotic drugs such as
aripiprazole.
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Title and abstract

Introduction
Background/rationale

Item
Recommendation
No
1
(a) Indicate the study’s design with a
commonly used term in the title or
the abstract
(b) Provide in the abstract an
informative and balanced summary
of what was done and what was
found
2

Objectives

3

Methods
Study design

4

Setting

5

Participants

6
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Data
sources/measurement
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7

8

9

Reported
Abstract

Abstract

Explain the scientific background
and rationale for the investigation
being reported
State specific objectives, including
any pre-specified hypotheses

Chapter 1,
2, 3, Figure
1
Chapter 3

Present key elements of study design
early in the paper
Describe the setting, locations, and
relevant dates, including periods of
recruitment, exposure, follow-up,
and data collection
(a) Give the eligibility criteria, and
the sources and methods of selection
of participants. Describe methods of
follow-up
(b) For matched studies, give
matching criteria and number of
exposed and unexposed
Clearly define all outcomes,
exposures, predictors, potential
confounders, and effect modifiers.
Give diagnostic criteria, if applicable
For each variable of interest, give
sources of data and details of
methods of assessment
(measurement). Describe
comparability of assessment methods
if there is more than one group
Describe any efforts to address
potential sources of bias

Chapter 4
Chapter 4

Chapter 4,
Figure 2

Chapter 4,
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Appendix B
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Chapter 4,
Appendix B,
Appendix C
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Appendix B,
Appendix C
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Chapter 6
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Study size
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Explain how the study size was
arrived at

Quantitative variables
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Statistical methods
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were handled in the analyses. If
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confounding
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(c) Explain how missing data were
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applicable, confounder-adjusted
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Appendix B: Coding definitions for demographics and comorbid conditions
Variable
Age
Sex
Income
(neighbourhood
income quintiles)
Location of residence
Residential status
Dementia

Database
RPDB
RPDB
Statistics
Canada
Statistics
Canada
ODB
CIHI-DAD

OMHRS

Schizophrenia or
other psychotic
disorder

OHIP
CIHI-DAD

OMHRS

Bipolar disorder

OHIP
CIHI-DAD

OMHRS

OHIP

Code

ICD-9 2900, 2901, 2903, 2904, 2908, 2909,
2948, 2949, 3310, 3311, 3312, 2941, 797
ICD-10 F065, F066, F068, F069, F09, F00,
F01, F02, F03, F051, G30, G31, R54
DSM-IV 29040, 29041, 29042, 29043, 29120,
29282, 29410, 29411, 29480, 78090
290, 331, 797
ICD-9 2950, 2951, 2952, 2953, 2954, 2955,
2956, 2957, 2958, 2959, 2970, 2971, 2972,
2973, 2978, 2979, 2980, 2981, 2983, 2984,
2988, 2989
ICD-10 F060, F062, F105, F107, F115, F117,
F125, F127, F135, F137, F145, F147, F155,
F157, F165, F167, F175, F177, F185, F187,
F195, F197, F200, F201, F202, F203, F204,
F205, F206, F208, F209, F220, F228, F229,
F230, F231, F232, F233, F238, F239, F24,
F250, F251, F252, F258, F259, F28, F29
DSM-IV 29130, 29150, 29211, 29212, 29381,
29382, 29510, 29520, 29530, 29540, 29560,
29570, 29590, 29710, 29730, 29880, 29890
291, 292, 295, 297, 298, Q021
ICD-9 2960, 2961, 2964, 2965, 2966, 2967,
2968
ICD-10 F300, F301, F302, F308, F309, F310,
F311, F312, F313, F314, F315, F316, F317,
F318, F319
DSM-IV 29600, 29601, 29602, 29603, 29604,
29605, 29606, 29640, 29641, 29642, 29643,
29644, 29645, 29646, 29650, 29651, 29652,
29653, 29654, 29655, 29656, 29660, 29661,
29662, 29663, 29664, 29665, 29666, 29670,
29680, 29689
296, Q020
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Major depression
and/or anxiety
disorder

CIHI-DAD

OMHRS

Chronic kidney
disease

Cerebrovascular
disease
Chronic liver disease

Congestive heart
failure

OHIP
CIHI-DAD

OHIP
CIHI-DAD

CIHI-DAD

OHIP
CIHI-DAD

ICD-9 2962, 2963, 3000, 3002, 3003, 3004,
3091, 311
ICD-10 F063, F064, F320, F321, F322, F323,
F328, F329, F330, F331, F332, F333, F334,
F338, F339, F341, F400, F401, F402, F408,
F409, F410, F411, F412, F413, F418, F419,
F420, F421, F422, F428, F429, F430, F431
DSM-IV 29189, 29284, 29289, 29383, 29384,
29620, 29621, 29622, 29623, 29624, 29625,
29626, 29630, 29631, 29632, 29633, 29634,
29635, 29636, 30000, 30001, 30002, 30021,
30022, 30023, 30029, 30030, 30040, 30113
311
ICD-9 4030, 4031, 4039, 4040, 4041, 4049,
582, 583, 580, 581, 584, 585, 586, 587, 5880,
5888, 5889, 5937
ICD-10 E102, E112, E132, E142, I12, I13,
N08, N18, N19
403, 585
ICD-9 434, 436, 431, 4358, 4359
ICD-10 H341, I630, I631, I632, I633, I634,
I635, I638, I639, I629, I64, G45, I61
ICD-9 4561, 4562, 070, 5722, 5723, 5724,
5728, 573, 7824, V026, 2750, 2751, 7891,
7895, 571
ICD-10 B16, B17, B18, B19, I85, R17, R18,
R160, R162, B942, Z225, E831, E830, K70,
K713, K714, K715, K717, K721, K729, K73,
K74, K753, K754, K758, K759, K76, K77
571, 573, 070, Z551, Z554
ICD-9 425, 5184, 514, 428
ICD-10 I500, I501, I509, I255, J81
CCP 4961, 4962, 4963, 4964

Coronary artery
disease

OHIP
CIHI-DAD

CCI 1HP53, 1HP55, 1HZ53GRFR,
1HZ53LAFR, 1HZ53SYFR
428, R701, R702, Z429
ICD-9 410 412, 413, 414, 4292, 4295, 4296,
4297
ICD-10 I20, I21, I22, I23, I24, I25, Z955,
Z958, Z959, R931, T822
CCP 4801, 4802, 4803, 4804, 4805, 481, 482,
483
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OHIP

Diabetes mellitus
Hypertension
Peripheral vascular
disease

ODB
ODB
CIHI-DAD

CCI 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76
410, 412, 413, R741, R742, R743, G298,
E646, E651, E652, E654, E655, G262, Z434,
Z448

ICD-9 4402, 4408, 4409, 5571, 4439, 444
ICD-10 I700, I702, I708, I709, I731, I738,
I739, K551
CCP 5125, 5129, 5014, 5016, 5018, 5028,
5038
CCI 1KA76, 1KA50, 1KE76, 1KG26,
1KG50, 1KG57, 1KG76MI, 1KG87

OHIP

Prescribing physician

R787, R780, R797, R804, R809, R875, R815,
R936, R783, R784, R785, E626, R814, R786,
R937, R860, R861, R855, R856, R933, R934,
R791, E672, R794, R813, R867, E649

ODB

CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of
Diagnostic, Therapeutic and Surgical Procedures; CIHI-DAD, Canadian Institute for
Health Information Discharge Abstract Database; ICD-9, International Classification of
Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth
Revision; ODB, Ontario Drug Benefit; OHIP, Ontario Health Insurance Plan; OMHRS,
Ontario Mental Health Reporting System; RPDB, Ontario’s Registered Persons
Database
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Appendix C: Coding definitions for hospitalized outcomes
Outcome
Primary outcome
Acute kidney injurya
Secondary outcomes
Hypotensionb
Acute urinary retentionb
Neuroleptic malignant
syndrome/rhabdomyolysis
Acute myocardial
infarctionc
Ventricular arrhythmia

All-cause mortalityd

Database

Code

CIHI-DAD

ICD-10 N17

CIHI-DAD
CIHI-DAD
CIHI-DAD

ICD-10 I95
R33
ICD-10 G210, M628, T796

CIHI-DAD

ICD-10 I21, I22

CIHI-DAD

ICD-10 I460, I469, I470, I472, I4900,
I4901,
CCI 1HZ09JAFS, 1HZ09JAJF,
1HZ30JN, 1HZ30JY
Vital status field

RPDB

Abbreviations: CCI, Canadian Classification of Health Interventions; CIHI-DAD,
Canadian Institute for Health Information Discharge Abstract Database; ICD-10,
International Classification of Diseases, Tenth Revision; RPDB, Ontario’s Registered
Persons Database
a
Validation of the code for acute kidney injury was performed on approximately 39 000
hospitalizations with linked laboratory measurements for serum creatinine. See
Methods section for a description of the validation.141
b
Using reabstracted information written in a patient’s chart as the reference standard,
the code for hypotension and acute urinary retention has a sensitivity of 72% and 86%,
and positive predictive value of 39% and 48%, respectively.142 This is a poor reference
standard compared to patient blood pressure measurements and post-void residual urine
volumes.
c
Code I21 (most responsible diagnosis) has a sensitivity of 89% and positive predictive
value of 87%.142
d
All-cause mortality has a sensitivity of 94% and specificity of 100%.143
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